Mylan may have overcharged U.S. for EpiPen by $1.27 billion: HHS

NEW YORK (Reuters) – The U.S. government may have overpaid drugmaker Mylan N.V. by as much as $1.27 billion between 2006 and 2016 for its EpiPen emergency allergy treatment, the Department of Health and Human Services said on Wednesday.

Leave a Reply

Your email address will not be published. Required fields are marked *